Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease.

Background: Sebelipase alfa (Kanuma®) is approved for patients with Wolman disease (WD) at a dosage of 3-5 mg/kg once weekly. Survival rates in the second of two clinical trials was greater, despite recruiting more severely ill patients, probably related to higher initial and maximal doses. We aimed to evaluate the effective pharmacokinetics and pharmacodynamics of Sebelipase alfa when administered to patients with severe WD at 5 mg/kg twice weekly, an intensive regimen which was not assessed in the trials.

Special Low Protein Foods Prescribed in England for PKU Patients: An Analysis of Prescribing Patterns and Cost.

Patients with phenylketonuria (PKU) are reliant on special low protein foods (SLPFs) as part of their dietary treatment. In England, several issues regarding the accessibility of SLPFs through the national prescribing system have been highlighted. Therefore, prescribing patterns and expenditure on all SLPFs available on prescription in England ( = 142) were examined.

Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease.

Background: Wolman disease is a rare, lysosomal storage disorder in which biallelic variants in the LIPA gene result in reduced or complete lack of lysosomal acid lipase. The accumulation of the substrates; cholesterol esters and triglycerides, significantly impacts cellular function. Untreated patients die within the first 12 months of life.

The natural history of glycogen storage disease type Ib in England: A multisite survey.

Glycogen storage disease type Ib (GSDIb) is characterized by hepatomegaly and fasting hypoglycaemia as well as neutropaenia and recurrent infections. We conducted a retrospective observational study on a cohort of patients with GSDIb across England. A total of 35 patients, with a median age of 9.

The use of continuous glucose monitoring in the practical management of glycogen storage disorders.

Continuous glucose monitoring systems (CGMS) are now in widespread use in diabetes management with an increasing evidence base. There are few reports of their use in GSD. Liver glycogen storage disorders (GSDs) are most often managed by intensive dietary regimens.

Blood phenylalanine control in adolescents with phenylketonuria.

In order to determine the degree of compliance with dietary treatment in adolescents with phenylketonuria (PKU) we have analysed blood phenylalanine (phe) results in 75 patients (42 male) aged between 10 and 20 years. We compared these results with the upper limit for blood phe and the blood sampling frequency as recommended by the United Kingdom's National Society for Phenylketonuria (NSPKU(UK)). The blood phe increased with age from a mean (1SD) of 0.